BEDFORD, Mass. , July 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, August 6, 2025 , to discuss its financial results and provide a business update for the second
BEDFORD, Mass. , July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group
BEDFORD, Mass. , June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings , Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new data
BEDFORD, Mass. , June 10, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison , Chief
BEDFORD, Mass. , June 03, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison , Chief
Worldwide revenue of $372.8 million in the first quarter 2025 GAAP fully diluted earnings per share of $1.02 , compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53 , compared to $1.69 in the first quarter of 2024 Free cash flow totaled $98.8 million for
Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite ® , NEUROLITE ® , Xenon Xe-133 Gas , and Cardiolite ® BEDFORD, Mass. , May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.
Company plans to file NDA in the third quarter of this year BEDFORD, Mass. , April 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings , Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better
BEDFORD, Mass. , April 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 , to discuss its financial and operating results for the first quarter of 2025.
BEDFORD, Mass. , April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it
Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024 Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024 GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full
BEDFORD, Mass. , Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced members of its management
BEDFORD, Mass. , Feb. 12, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025 , to discuss its financial and operating results for the fourth quarter and full
Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSA Real-world evidence of PYLARIFY’s effectiveness in prostate cancer being presented BEDFORD, Mass. , Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings , Inc. (the Company) (NASDAQ: LNTH), the leading
BEDFORD, Mass. , Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™ , a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus’ therapeutic agent, PNT2003
Enhances Lantheus’ growth profile with Neuraceq ® , a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s Disease Advances Lantheus’ radiopharmaceutical leadership with addition of Alzheimer’s radiodiagnostic commercial infrastructure,
